The targeting of pharmaceuticals is a rapidly evolving strategy to overcome the difficulties in therapeutic delivery, especially to the tumor site. Unlike traditional drug delivery systems, nanoparticles based compounds attain superior accretion in the tumor site by their active or passive mechanisms. Due to their exclusive properties like small size, large surface-to-volume ratio, tunable surface chemistry, and the ability to encapsulate various drugs, the nano-sized carriers provide longer circulation time; easy penetration into cellular membranes; efficient site-specific targeting. Recent advancements in polymeric- nanomedicines involve targeting of polymer-based nanoparticles (NPs), micelles, polyplexes, dendrimers, polymersomes, drug/protein conjugates and lipid hybrid systems to tumor pathological site. With different functional moieties, NPs improve the performance in terms of targetability, circulation longevity, enhanced intracellular penetration, stimuli-sensitivity, and carrier-mediated visualization. This review highlighted different preparative techniques and types of nanoparticles in the most recent developments in cancer treatment including promising opportunities in targeted; combination therapy; and other medical and biomedical applications. Various delivery strategies and future prospects of nanoparticles are also enlisted. Apart from that, the review discusses the potential advances and targeting of polymeric nanocarriers within the scope of cancer therapeutic system to emphasize it as an auxiliary tool to the customary drug delivery systems.

The establishment of a healthy microbiota, particularly during infancy, profoundly influences psychological health and neurological function through the gut‐brain axis. This review delves into the intricate connections between probiotics, gut microbiome development, and their impact on neurological disorders. Biotics, live microorganisms with proven health benefits, have emerged as a promising intervention, particularly during critical developmental stages. Administering specific probiotic strains (Lactobacillus species and Bifidobacterium) in infancy has shown promise in preventing and alleviating gut disorders, with implications for psychological well‐being. The bidirectional communication along the gut‐brain axis underscores the potential of probiotics in influencing neurological outcomes, ranging from anxiety to neurodevelopmental disorders. Additionally, this review explores emerging food engineering techniques (microencapsulation, genome editing, fermentation, protein engineering, immobilization, etc.) employed in preparing probiotic‐based foods, ensuring the viability and targeted release of probiotics in the gastrointestinal tract.

A gradient reverse phase high pressure liquid chromatographic method has been proposed for simultaneous determination and separation of curcumin (CUR), bisdemethoxycurcumin (BMC), demethoxycurcumin (DMC), and metanil yellow (MET). The separation was achieved on an Agilent Eclipse XDB-C18 (4.6 mm × 150 mm, 3.5 µm) analytical column using photodiode array (PDA) detection at 425 nm. Gradient elution of solvent A (mixture of 0.1% trifluoro acetic acid and 0.1% formic acid 50:50 v/v) and solvent B (acetonitrile) at a flow rate of 0.8 mL/min was used to accomplish adequate separation of the analytes. The developed method was extensively validated with respect to linearity, detection and quantitation limits, precision, recovery, and robustness testing. Method variables, viz., mobile phase flow rate (0.90 ± 0.05 mL/min), percentage of B at start of gradient (40 ± 2%) and detection wavelength (425 ± 5 nm) were studied by a Box–Behnken Design (BBD) for testing the robustness of the proposed method. The method was found robust, with no significant variations in the method performance, linear in the range of 10–80 µg/mL (r² = 0.999) and precise (RSD ˂ 2%) satisfying regulatory criteria. The method is selective for rapid determination of turmeric adulteration with a detection limit of 0.37–2.48 µg/mL.